Emergent BioSolutions Inc. (EBS)
NYSE: EBS · Real-Time Price · USD
5.60
+0.23 (4.28%)
Apr 25, 2025, 12:39 PM EDT - Market open
Emergent BioSolutions Revenue
In the year 2024, Emergent BioSolutions had annual revenue of $1.04B, down -0.54%. Emergent BioSolutions had revenue of $194.70M in the quarter ending December 31, 2024, a decrease of -29.61%.
Revenue (ttm)
$1.04B
Revenue Growth
-0.54%
P/S Ratio
0.27
Revenue / Employee
$1,159,556
Employees
900
Market Cap
304.29M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.04B | -5.70M | -0.54% |
| Dec 31, 2023 | 1.05B | -68.20M | -6.10% |
| Dec 31, 2022 | 1.12B | -656.10M | -36.99% |
| Dec 31, 2021 | 1.77B | 196.30M | 12.45% |
| Dec 31, 2020 | 1.58B | 471.30M | 42.61% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.90B |
EBS News
- 3 days ago - Emergent BioSolutions to Report First Quarter 2025 Financial Results on May 7, 2025 - GlobeNewsWire
- 25 days ago - Emergent BioSolutions Announces Stock Repurchase Program - GlobeNewsWire
- 5 weeks ago - Emergent BioSolutions New Hire Equity Grant Under NYSE Rule 303A.08 - GlobeNewsWire
- 5 weeks ago - Hikma announces Health Canada approval of KLOXXADO® (naloxone HCl) Nasal Spray 8 mg - GlobeNewsWire
- 5 weeks ago - Emergent BioSolutions Finalizes Sale of Baltimore-Bayview Manufacturing Site to Syngene International - GlobeNewsWire
- 5 weeks ago - Emergent BioSolutions Announces Approximately $27 Million in Incremental Sales to Supply International Customers with Five Critical Medical Countermeasure Products - GlobeNewsWire
- 6 weeks ago - Emergent BioSolutions Reinforces its Commitment to Expanding Access to NARCAN® Nasal Spray by Supporting Organizations with New Opioid Overdose Preparedness Programs - GlobeNewsWire
- 6 weeks ago - Emergent BioSolutions and Rocketvax Announce Investment Agreement and Pursuit of a Strategic Relationship for Next-Generation Product Candidates - GlobeNewsWire